Leveraging high-fidelity neural architectures and predictive enrollment modeling to de-risk therapeutic R&D and compress the pathway to market. Sabalynx integrates multi-modal data pipelines to mitigate patient attrition, automate protocol feasibility analysis, and ensure robust statistical power for global regulatory submission.
Modern clinical development faces a dual crisis: exponentially rising costs and increasing protocol complexity. We resolve this by deploying bespoke AI engines that transform unstructured clinical data into actionable R&D intelligence.
Protocol failure is frequently a result of poor site selection and unrealistic inclusion/exclusion criteria. Our AI models analyze Real-World Data (RWD) and Electronic Health Records (EHR) to predict patient density and recruitment velocity with 94% accuracy.
Using advanced Natural Language Processing (NLP) and Large Language Models (LLMs) specialized in medical semantics, Sabalynx automates the digitization of trial protocols. This identifies hidden logistical burdens and predicts potential amendments before the trial initiates, saving millions in operational overhead.
Our proprietary engines cross-reference clinical history from over 10,000 previous trials to identify patterns of success and failure. We don’t just provide data; we provide a predictive roadmap for regulatory success.
Clustering algorithms identify sub-populations most likely to respond to the investigational product, maximizing the signal-to-noise ratio in phase II and III trials.
Deploying RWD-derived control groups to reduce the number of patients required on placebos, accelerating trials and enhancing ethical alignment.
Ingesting silos of EDC, CTMS, and Lab data into a unified, GxP-compliant clinical data lake for unified analysis.
2 WeeksSimulating recruitment scenarios using historical site performance and patient geographical distribution data.
4 WeeksRunning protocol stress tests against digital twins to identify potential endpoints that lack sufficient statistical sensitivity.
6 WeeksReal-time risk-based monitoring (RBM) to detect anomalies in data entry or site performance before they become critical.
OngoingOur technical leads are ready to demonstrate how AI clinical trial optimisation can deliver a 40% reduction in your phase III timelines. Let’s discuss your protocol and data architecture.
Navigating the high-stakes transition from heuristic-driven protocols to predictive, data-centric drug development architectures.
The pharmaceutical industry is currently grappling with “Eroom’s Law”—the observation that drug discovery is becoming slower and more expensive despite massive technological advancements. Today, the average cost to bring a new molecule to market exceeds $2.6 billion, with clinical trials accounting for up to 60% of that expenditure.
Legacy Clinical Research Organisation (CRO) models are failing because they rely on retrospective data and manual site selection. Approximately 80% of trials fail to meet enrollment timelines, and 30% of patients drop out after the trial has commenced. This inefficiency isn’t just a logistical hurdle; it is a multi-billion dollar revenue leakage. For a potential blockbuster drug, every single day of delay in market entry represents between $1 million and $10 million in lost opportunity cost.
By integrating Advanced Neural Networks and Large Language Models (LLMs) into the pre-clinical and phase I-III pipelines, Sabalynx enables sponsors to compress timelines by up to 40% while maintaining rigorous regulatory compliance.
We leverage NLP-driven analysis of historical trial data and real-world evidence (RWE) to simulate protocol amendments before they reach the IRB. This prevents costly “rescue” amendments mid-study.
Moving beyond broad demographics, our AI models ingest unstructured Electronic Health Records (EHR) and genomic data to identify high-affinity patients with surgical precision across global sites.
Reduce the number of patients required for the placebo arm by using AI to generate high-fidelity synthetic control groups from historical data, drastically accelerating Phase II and III timelines.
A robust AI clinical trial engine requires more than just algorithms; it requires a specialized data pipeline built for privacy and performance.
The primary barrier to clinical AI is data sovereignty. We deploy federated learning architectures that allow models to be trained across multiple hospital networks and clinical sites without sensitive patient data ever leaving its original source, ensuring HIPAA and GDPR compliance while maximizing model accuracy.
By integrating wearable IoT data and ePRO (Electronic Patient-Reported Outcomes) into an MLOps pipeline, our systems can predict patient attrition weeks before it happens. This allows for proactive intervention, drastically reducing the “churn” rate of participants and preserving the statistical power of the trial.
We utilize specialized RAG (Retrieval-Augmented Generation) systems to assist medical writers in synthesizing Clinical Study Reports (CSRs). By ensuring consistency across thousands of pages of trial data, we minimize the risk of FDA Refusal-to-File (RTF) actions, which can be catastrophic to a sponsor’s valuation.
The transition to AI-optimized trials is no longer optional—it is the baseline for competitive drug development. Sabalynx provides the technical bridge between experimental AI and regulatory-grade deployment.
Moving beyond legacy trial management. Our architecture integrates high-dimensional data pipelines with sovereign AI models to collapse the clinical development lifecycle from years to months.
At the core of Sabalynx’s AI Clinical Trial Optimisation platform is a sophisticated Data Orchestration Layer designed to ingest and harmonise disparate data streams. In the pharmaceutical sector, the challenge is rarely a lack of data; it is the extreme fragmentation across Electronic Health Records (EHR), Medical Imaging (DICOM), genomic sequencing (VCF), and real-world evidence (RWE).
Our architecture utilises Federated Learning frameworks, allowing models to train across hospital networks and private repositories without the underlying sensitive patient data ever leaving the secure perimeter. This “data-to-model” approach bypasses traditional ETL bottlenecks and ensures 100% compliance with HIPAA, GDPR, and local sovereign data laws.
By deploying Graph Neural Networks (GNNs), we map the complex relationships between biomarkers, comorbidities, and historical trial outcomes. This creates a “Digital Twin” of the clinical trial environment, allowing PIs and Clinical Operations leads to run in-silico simulations before a single patient is ever enrolled, significantly reducing the risk of Phase II/III failures.
Leverage historical trial data and RWE to generate high-fidelity control cohorts. This reduces the number of human subjects required for placebo groups, accelerating time-to-market and lowering recruitment costs by up to 30%.
Advanced Transformer-based models analyse longitudinal health records to identify high-probability “super-responders.” By optimizing inclusion/exclusion criteria via AI, we minimize screen-fail rates and enhance signal detection.
Our NLP-driven monitoring layer scans clinician notes and patient diaries in real-time, identifying safety signals and potential adverse events (AEs) weeks before manual review processes, ensuring superior patient safety.
A rigorous machine learning operations pipeline ensuring model reproducibility, versioning, and explainability (XAI). Every prediction includes a confidence score and feature importance map for regulatory transparency.
Normalizing OMOP Common Data Models and FHIR standards across global sites to create a unified, AI-ready substrate.
Week 1-4Running Monte Carlo simulations on patient cohorts to predict recruitment velocity and optimize trial endpoints.
Week 5-8Deploying agentic AI to match patients to trials at the point of care, significantly reducing manual screening burdens.
ContinuousGenerating automated, AI-augmented clinical study reports (CSR) with full auditability for FDA/EMA scrutiny.
Final PhaseOur architects are ready to discuss specific integration points for your existing clinical stack (Medidata, Veeva, Oracle) and how our AI pipelines can sit on top of your current data lake.
The traditional clinical trial paradigm is fractured by escalating costs, high attrition rates, and data silos. Sabalynx deploys advanced neural architectures and federated data pipelines to transition Life Sciences organisations from reactive to predictive clinical operations. By integrating Generative AI, Digital Twins, and Real-World Evidence (RWE), we compress the drug development lifecycle and maximize the probability of regulatory success.
The industry standard for patient recruitment remains inefficient, with 80% of trials failing to meet enrollment timelines. Sabalynx implements Large Language Models (LLMs) and Knowledge Graphs to parse unstructured Electronic Medical Records (EMR) and cross-reference them against complex inclusion/exclusion criteria. This semantic alignment identifies eligible cohorts with surgical precision, reducing screening failures by up to 45%.
In rare disease research or oncology, recruiting a placebo group is often ethically complex and cost-prohibitive. We engineer high-fidelity Synthetic Control Arms (SCAs) using historical trial data and RWE processed through GANs. These AI-generated patient cohorts mimic the statistical properties of real-world patients, allowing sponsors to reduce the number of live participants required while maintaining rigorous regulatory validity.
Protocol amendments cost the industry billions annually. Our “In Silico” trial simulation engine utilizes Digital Twins of patients to predict biological responses to various dosage regimens and titration schedules. By simulating thousands of trial iterations before the first patient is even dosed, we identify potential endpoint failures early, optimizing the protocol for a significantly higher Probability of Technical Success (PoTS).
Patient dropout is a silent killer of trial power. Sabalynx deploys Recurrent Neural Networks (RNNs) that analyze longitudinal data streams from wearables and digital health apps. By detecting subtle deviations in biometric signatures or engagement patterns, our AI predicts “at-risk” patients before they withdraw, enabling clinical sites to intervene with personalized support and increasing overall retention rates by 30%.
Selecting the wrong clinical sites leads to non-performing centers that drain resources. We utilize spatio-temporal modeling to evaluate global healthcare infrastructure, local disease prevalence, and historical investigator performance. Our platform forecasts enrollment curves with 90%+ accuracy, allowing operations teams to dynamically allocate resources to the most productive geographic regions and sites.
Monitoring safety signals in large populations post-approval is a massive data challenge. Sabalynx implements Natural Language Understanding (NLU) pipelines to monitor diverse real-world data sources, including social media, medical forums, and insurance claims. This automated surveillance identifies potential adverse events (AEs) significantly faster than traditional spontaneous reporting, ensuring patient safety and regulatory compliance.
Sabalynx doesn’t just provide software; we engineer the data pipelines that make AI possible in a highly regulated GxP environment. Our architecture is designed for data integrity, traceability, and high-performance computing.
Train AI models across multiple hospital systems without moving sensitive patient data out of their secure firewalls. This ensures HIPAA/GDPR compliance while accessing massive, diverse datasets.
We utilize SHAP and LIME methodologies to ensure every AI-driven decision—from patient screening to endpoint prediction—is interpretable and defensible to the FDA and EMA.
Connect with our Life Sciences AI consultants to discuss your clinical strategy. We provide comprehensive ROI analysis and technical roadmaps tailored to your therapeutic focus.
The promise of AI in life sciences is frequently obscured by oversimplified marketing. As consultants who have navigated the high-stakes intersection of Machine Learning and GxP compliance, we know that successful deployment requires more than just an API call to an LLM. It requires an uncompromising focus on data provenance, algorithmic transparency, and regulatory fortification.
Most AI initiatives fail because they underestimate the complexity of ingesting EMR, genomic, and wearable data. Without a robust OMOP Common Data Model or FHIR-based integration strategy, your “intelligent” system will be starved by fragmented, non-interoperable silos that lack the longitudinal depth required for predictive modeling.
Infrastructure RiskGenerative AI is inherently stochastic, introducing the risk of “hallucinations” in clinical document synthesis or protocol design. In a highly regulated environment, a 5% error rate isn’t just a bug—it’s a multi-million dollar regulatory liability. We implement RAG (Retrieval-Augmented Generation) with rigorous human-in-the-loop validation to enforce factual grounding.
Validation RiskAI-driven patient matching often inadvertently replicates the socio-economic and ethnic biases present in historical trial data. If your recruitment algorithm isn’t audited for demographic parity and representation, you risk both scientific invalidity and rejection from agencies like the FDA, which are increasingly mandating diversity action plans.
Compliance RiskDeep learning models are notoriously opaque. However, for 21 CFR Part 11 compliance, “computer said so” is not a valid justification. We utilize SHAP and LIME-based Explainable AI (XAI) frameworks to ensure that every prediction—from patient dropout risk to site selection—is backed by a defensible and interpretable audit trail.
Audit RiskWe don’t just build AI. We engineer outcomes — measurable, defensible, transformative results that justify every dollar of your investment.
Every engagement starts with defining your success metrics. We commit to measurable outcomes — not just delivery milestones.
Our team spans 15+ countries. We combine world-class AI expertise with deep understanding of regional regulatory requirements.
Ethical AI is embedded into every solution from day one. We build for fairness, transparency, and long-term trustworthiness.
Strategy. Development. Deployment. Monitoring. We handle the full AI lifecycle — no third-party handoffs, no production surprises.
Pharmaceutical R&D faces a structural crisis: 90% of drugs that enter clinical trials fail to reach approval, and the cost of bringing a single molecule to market now exceeds $2.6 billion. Sabalynx transforms this paradigm by deploying state-of-the-art Machine Learning (ML) and Large Language Models (LLMs) across the entire Clinical Trial Management System (CTMS) lifecycle.
We leverage Retrieval-Augmented Generation (RAG) and specialized Bio-Transformers to analyze hundreds of thousands of historical trial outcomes. By identifying subtle correlations between inclusion/exclusion criteria and attrition rates, our models predict trial success probability with 85% accuracy before the first patient is even enrolled. This minimizes protocol amendments—a primary driver of cost overruns.
Patient recruitment remains the single greatest bottleneck in clinical research. Sabalynx deploys predictive analytics to map high-density patient clusters using Real-World Data (RWD) and Electronic Health Records (EHR). Our algorithms go beyond demographic matching, utilizing multi-modal data fusion to predict patient adherence and identify genetic biomarkers that maximize treatment efficacy response.
By applying Bayesian inference and generative modeling, we construct high-fidelity Synthetic Control Arms. These digital cohorts reduce the requirement for large placebo groups, accelerating trial completion by up to 40% and addressing ethical concerns in rare disease research. Our SCAs are built to withstand rigorous regulatory scrutiny from the FDA and EMA, ensuring statistical validity through Propensity Score Matching (PSM).
Modern AI Clinical Trial Optimisation requires more than just predictive models; it requires a robust MLOps pipeline capable of handling sensitive, heterogeneous datasets while maintaining strict GxP (Good Practice) compliance.
At Sabalynx, we architect end-to-end data pipelines that utilize federated learning to train models on siloed institutional data without compromising patient privacy. Our “Human-in-the-loop” (HITL) interfaces allow clinical researchers to query model decisions through Explainable AI (XAI) frameworks like SHAP and LIME, ensuring that model output is not just accurate, but clinically interpretable.
Automated anomaly detection identifies data integrity issues in real-time, reducing the need for manual Site Monitoring Visits (SMVs).
Hyper-stratification of patient cohorts based on genomic markers increases the signal-to-noise ratio in early-phase trials.
AI models specifically architected to identify and correct for sampling bias, ensuring trials meet modern regulatory requirements for ethnic and geographic diversity.
Connect with our Principal AI Architects to discuss how Sabalynx can optimize your specific clinical pipeline. From protocol stress-testing to synthetic cohort construction, we engineer the competitive advantage your R&D department requires.
The current pharmaceutical landscape is defined by the “Eroom’s Law” phenomenon—where the cost of developing new drugs doubles approximately every nine years despite technological advances. For CROs and Sponsors, the primary bottlenecks remain patient recruitment attrition, manual protocol drafting, and the high failure rate of Phase II/III transitions. Sabalynx intervenes at the architectural level, deploying Agentic AI workflows that transform clinical trials from linear, reactive processes into predictive, high-velocity data pipelines.
Our approach leverages Large Language Models (LLMs) for Protocol Digitization and Multimodal Deep Learning to ingest Electronic Health Records (EHR) and Real-World Evidence (RWE). By implementing Synthetic Control Arms (SCA) and Bayesian Enrollment Modelling, we reduce the dependency on physical recruitment centers and mitigate the risk of underpowered studies. This is not merely digital transformation; it is the implementation of a Clinical Intelligence Layer that ensures regulatory submission readiness from day one.
Analyzing current trial designs for “In-Silico” simulation opportunities to reduce patient burden and cohort size.
Identifying site selection risks through geospatial AI and predictive phenotyping of potential candidates.
Reviewing EDC/EHR interoperability and AI-readiness for automated Adverse Event (AE) signal detection.
A data-driven estimate of how much AI can shave off your clinical trial timelines and associated costs per patient.
Sabalynx specializes in the deployment of Custom LLMs (Large Language Models) for the life sciences sector. Unlike generic AI wrappers, our models are fine-tuned on PubMed, clinicaltrials.gov, and proprietary historical trial data to assist medical writers in generating CSRs (Clinical Study Reports) and eCTD (Electronic Common Technical Document) sections. We move beyond simple automation into Agentic AI, where autonomous agents monitor data streams for protocol deviations and trigger proactive intervention alerts, ensuring trial integrity while reducing the monitoring burden on CRAs (Clinical Research Associates).